Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H29N5O7 |
| Molecular Weight | 499.5164 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)NCC(O)=O
InChI
InChIKey=BGFPKYKDLYYTJH-OALUTQOASA-N
InChI=1S/C24H29N5O7/c25-18(10-16-6-8-17(30)9-7-16)23(35)27-13-21(32)29-19(11-15-4-2-1-3-5-15)24(36)28-12-20(31)26-14-22(33)34/h1-9,18-19,30H,10-14,25H2,(H,26,31)(H,27,35)(H,28,36)(H,29,32)(H,33,34)/t18-,19-/m0/s1
| Molecular Formula | C24H29N5O7 |
| Molecular Weight | 499.5164 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 19:21:27 GMT 2025
by
admin
on
Wed Apr 02 19:21:27 GMT 2025
|
| Record UNII |
75F9CVQ7Y2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
105250-85-9
Created by
admin on Wed Apr 02 19:21:27 GMT 2025 , Edited by admin on Wed Apr 02 19:21:27 GMT 2025
|
PRIMARY | |||
|
DTXSID10909398
Created by
admin on Wed Apr 02 19:21:27 GMT 2025 , Edited by admin on Wed Apr 02 19:21:27 GMT 2025
|
PRIMARY | |||
|
147077
Created by
admin on Wed Apr 02 19:21:27 GMT 2025 , Edited by admin on Wed Apr 02 19:21:27 GMT 2025
|
PRIMARY | |||
|
75F9CVQ7Y2
Created by
admin on Wed Apr 02 19:21:27 GMT 2025 , Edited by admin on Wed Apr 02 19:21:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In addition to stimulating bone formation, OGP(10-14) shows hematological activity. In fact, it highly enhances hematopoiesis-affecting stem progenitors. Moreover, OGP(10-14) reduces the growth and induces the differentiation of the hematological tumour cell line trombophoietin(TPO)-primed M07-e by interfering with RhoA and Src kinase pathways.
|
